How Long Covid Families Shapes Pediatric Long COVID Research

At a Glance
- Bringing family experience and scientific expertise into research
- Shaping RECOVER from early planning through publication
- Using findings to advocate for access to care and education
Long COVID can look different at different ages. Research needs to account for those differences. For six years, Long Covid Families (LCF) has helped pediatric Long COVID research ask the questions that matter to children.
Our role starts before a study is funded and continues after it is published. We share the findings and bring them to the people who make decisions about children’s access to medical care and education.
Where Our Expertise Comes From
Caregivers are part of our leadership, and we were founded by someone who grew up with a similar illness after an infection.
We’ve held listening sessions with more than 500 families and have surveyed families regularly for the past five years. Those conversations help us understand what daily life is like for a child. The surveys help us see which concerns come up across families.
“As parents, we live with the questions research has yet to answer. At Long Covid Families, we help shape the questions researchers ask so the work reflects what matters in our children’s lives.”
—Rochelle, Long Covid Families board member and parent
We bring our own research expertise to the work.
Formed in 2026, our Scientific Board is part of LCF’s leadership team. Dr. Alessandra Angelino chairs the board of eleven scientists and pediatric clinicians. Members help us make sense of the research and the questions it has yet to answer. Their advice shapes our Pediatric Long COVID Research Brief. It also guides our resources for people who make decisions about children’s medical care and education.
Research Partnerships
We help researchers shape the questions a study will ask, drawing on our research expertise and years of working with families. Some partnerships begin before a team applies for funding, with plans for us to stay involved if the grant is awarded.
We also work on studies that have already received funding. As researchers review their results, we help decide what to explore further and discuss what the findings mean for children.
RECOVER 1.0 and 2.0
RECOVER, the National Institutes of Health (NIH) research program on Long COVID, follows children to learn how the illness changes as they grow. Researchers want to understand why some improve while others stay sick. This part of RECOVER studies their health without testing a treatment.
LCF’s involvement began with RECOVER 1.0. Since 2022, our founder and president, Megan Carmilani, has served as a voting member of its Pediatric Coordinating Committee. She brings what we learn from families and her own childhood experience to every research meeting. We helped shape the pediatric study, including which questions it should ask about children’s lives and schooling.
We helped shape RECOVER 2.0 from its earliest planning meetings, contributing to decisions about the study’s research priorities and the questions it would ask.
The first phase included more than 15,000 children and young adults. Starting in early 2027, RECOVER 2.0 will keep following more than 4,300 participants through 2029.
The larger number counts everyone who took part in the first phase. The next phase follows a smaller group already selected for follow-up over several years. It also includes young children from RECOVER’s pregnancy study.
Researchers will use blood samples and other tests to look at what is happening inside children’s bodies. That includes signs of inflammation and changes around puberty. They will also ask more about school and the support children receive there.
We also help shape treatment research. RECOVER TLC, the NIH program that chooses Long COVID treatments to test, asked us which treatment children needed. We recommended low dose naltrexone. In 2025, NIH announced a trial of the drug for children. We have worked on the trial since its early stages.
Published Research
Members of our leadership team have coauthored RECOVER studies of Long COVID at different ages.
A 2024 JAMA study, Characterizing Long COVID in Children and Adolescents, covered children ages 6 to 17. It found different symptom patterns in school-age children and teenagers.
A 2025 JAMA Pediatrics study, Characterizing Long COVID Symptoms During Early Childhood, covered infants, toddlers and preschoolers. It found symptom patterns in these young children that differed from those seen at older ages.
We helped decide what the RECOVER school study would examine and coauthored School Difficulties and Long COVID in Children and Adolescents, published in Academic Pediatrics in 2026. Caregivers of children and teens with Long COVID were about twice as likely to report worsening grades as caregivers of those without it.
Why Our Role Matters
We use findings to make the case for better access to medical care and education. The school study gives us evidence for discussions about school support, linking what researchers learn with the decisions that shape a child’s education.
Videos on Pediatric Long COVID Research
Pediatric Long COVID research, including the NIH RECOVER pediatric study.
See what our work has helped achieve.


